...; Xiaochen Tang; Junbang Wang; Jie Liu; Michael Humphries, MD; Ping Li, MD; Yihong Yao, PhD; Aibin Liang, MD PhD Background: Relapse due to loss of the CD19 targeted epitope presents a therapeutic challenge of CD19 CAR-T therapy. These patients universally have poor outcomes. CD20 is a proven therapeutic...

...Wei Cui; Xinyue Zhang; Haiping Dai; Qingya Cui; Baoquan Song; Depei Wu, MDPhD; Xiaowen Tang, MD PhD; Jia Yin; Zheng Li Background: CD19 chimeric antigen receptor (CAR) T-cells therapy has shown unprecedented success in relapsed/refractory (r/r) ALL. Now it is recommended for the treatment...

... is expressed on the majority of B-cell malignancies. Autologous CAR T-cells targeting CD22 (CAR22) have yielded objective response rates (ORR) of 70-90% in pediatric patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), including those who had previously failed CD19-directed CAR T...

... PhD; Cameron J. Turtle, MBBS, PhD Background: CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for relapsed or refractory (R/R) B-cell malignancies, but lack of durable complete response (CR) is still seen in most patients. Enhancing in vivo T...

...Satoru Aoyama, MD; Shunichiro Yasuda, MD; Daisuke Watanabe, MD, PhD; Hiroki Akiyama, MD, PhD; Yoshihiro Umezawa, MD, PhD; Ayako Nogami, MD, PhD, BPharm; Osamu Miura, MD, PhD; Norihiko Kawamata, MD, PhD 【 Introduction 】 CAR-T cell therapy has shown excellent therapeutic effects against some...

...Sherly Mardiana, PhD; Olga Shestova, PhD; Marco Ruella, MD; Saar Gill, MD PhD BACKGROUND Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies, as highlighted by high complete remission rates and FDA approval of CD19-specific CAR...

... progression, but in the absence of curative options patients ultimately succumb to their disease. Chimeric Antigen Receptor (CAR) T cell therapy is potentially curative, but only 26% of CLL patients have a complete response. CLL-stimulated T cells have reduced effector functions and B-CLL cells themselves...

...Leah Alabanza, PhD; Bang Vu, PhD; Darong Wu, MS; Zhongyu Zhu, PhD; Boro Dropulic, PhDMBA; Dina Schneider, PhD The B-cell maturation antigen (BCMA) is an immunotherapy target selectively expressed on multiple myeloma cells (MM). Despite recent success of experimental BCMA CAR-T cell therapy...

...Peirong Hu, PhD; Ying Xiong, PhD; Darong Wu, MS; Zhongyu Zhu, PhD; Boro Dropulic, PhDMBA; Dina Schneider, PhD In the treatment of B cell leukemia, relapse due to antigen to loss or downregulation remains a major challenge. Tumor antigen escape may be mitigated by multi-targeting CAR T cells...

... (CAR) T cells has shown significant efficacy in B-cell malignancies, CAR T cells directed against CD30 (CAR30) for the treatment of Hodgkin lymphoma (HL) showed modest antitumor effect, with more than 50% of patients being unresponsive. Several factors related to the infused product and persistence may...

...Moriah Rabin, MD; Mengyan Li, PhD; Scott Garforth, PhD; Jacqueline Marino, BA; Jian Hua Zheng, BS; Kaitlyn E. O'Connor, BS; Steven C. Almo, PhD; Harris Goldstein, MD Background: While chimeric antigen receptor T cells (CAR T-cells) induce dramatic remissions of refractory or recurrent B cell...

... Savoldo, MD PhD Introduction: CAR-T cells targeting the CD19 antigen are approved to treat children and young adults with relapsed and refractory B-cell ALL, in whom response rates are >80%. Acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity...

... Zhang, MD; Xiaochen Tang; Junbang Wang; Jie Liu; Michael Humphries, MD; Ping Li, MD; Yihong Yao, PhD; Aibin Liang, MD PhD Background: Aiming to improve both the response rate and durability of response while limiting antigen escape of CD-19 following anti-CD-19 CAR-T therapy, C-CAR039 has been developed...

... as a result of the proliferation and on target cell kill by chimeric antigen receptor (CAR)-T cells, cytokine release syndrome (CRS) can be potentially targeted by adoptive therapy with T regulatory (Treg) cells. Specifically, allogeneic cord blood (CB) derived Treg cells have now shown safety and efficacy...

... Mao, PhD; Nathan Martin, PhD; Timothy B. Campbell, MD PhD; Kristen Hege; Hans Bitter, PhD; Fabio Petrocca, MD; Jesus G. Berdeja, MD Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B-cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed...

...) as a peripheral surrogate measure of tumor burden, and peripheral blood mononuclear cells were assessed by flow cytometry for memory phenotypes of CAR T cells. Associations between these features over time after ide-cel infusion were evaluated in the context of ORR, ongoing response at 9 mo, and grade ≥2 CRS...

...; Wei-Ting Hwang, PhD; Don L. Siegel, MD PhD; Bruce L Levine, PhD; Carl H June, MD; David L. Porter, MD INTRODUCTION Anti-CD19 CAR T-cell immunotherapy is promising for patients with relapsed/refractory CLL. Hypogammaglobinemia can result from normal CD19+ B-cell depletion by CAR-T cells. CLL patients...

...Noemie Leblay, PhD; Ranjan Maity, PhD; Elie Barakat; Sylvia McCulloch, MD MSc; Peter Duggan, MD FRCPC; Victor Jimenez-Zepeda, MD; Nizar J. Bahlis, MD; Paola Neri, MD Adaptive T cell therapy using chimeric antigen receptor (CAR) T cells and bispecific T cell engagers (BiTEs) have demonstrated...

...Reginald M Atkins, PhD; Meghan A Menges; Alexis Bauer, BS; Joel G. Turner, PhD; Frederick L. Locke, MD Background: Remarkable durable responses are seen with chimeric antigen receptor (CAR) T cell therapy in B cell lymphoma, however the majority of patients relapse (Locke et al. Lancet Oncol. 2019...

...: Tisagenlecleucel (Tisagen) and Axicabtagene Ciloleucel (Axicel) CD19 CAR T-cell products are licensed in the UK for adults with relapsed/refractory high-grade B-cell Non-Hodgkin's lymphoma (B-NHL). Infection rates for the first 30 days post CAR T range from 23% (Hill et al, Blood 2018) to 42% (Park et al, Clin...